A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Oxymetazoline
Cortisone acetate
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Hydroxychloroquine.
Oxymetazoline
Corticotropin
The risk or severity of adverse effects can be increased when Corticotropin is combined with Hydroxychloroquine.
Oxymetazoline
Nelarabine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Hydroxychloroquine.
Oxymetazoline
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Hydroxychloroquine.
Oxymetazoline
Lomustine
The risk or severity of adverse effects can be increased when Lomustine is combined with Hydroxychloroquine.
Oxymetazoline
Ifosfamide
The risk or severity of adverse effects can be increased when Ifosfamide is combined with Hydroxychloroquine.
Oxymetazoline
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Hydroxychloroquine.
Oxymetazoline
Trilostane
The risk or severity of adverse effects can be increased when Trilostane is combined with Hydroxychloroquine.
Oxymetazoline
Capecitabine
The risk or severity of adverse effects can be increased when Capecitabine is combined with Hydroxychloroquine.
Oxymetazoline
Flucytosine
The risk or severity of adverse effects can be increased when Flucytosine is combined with Hydroxychloroquine.
Oxymetazoline
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Hydroxychloroquine.
Oxymetazoline
Mycophenolic acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydroxychloroquine.
Oxymetazoline
Hydroxyurea
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Hydroxychloroquine.
Oxymetazoline
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Hydroxychloroquine.
Maprotiline
Dalfampridine
The risk or severity of seizure can be increased when Valganciclovir is combined with Dalfampridine.
Maprotiline
Amifampridine
The risk or severity of seizure can be increased when Valganciclovir is combined with Amifampridine.
Maprotiline
Cenobamate
The therapeutic efficacy of Cenobamate can be decreased when used in combination with Valganciclovir.
Maprotiline
JNJ-26489112
The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Valganciclovir.
Maprotiline
Eslicarbazepine
The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Valganciclovir.
Maprotiline
Cannabidivarin
The therapeutic efficacy of Cannabidivarin can be decreased when used in combination with Valganciclovir.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3